Vera Therapeutics (VERA) is back on investors’ radar after Deerfield Management Company added 418,538 shares in the fourth quarter, as the market watches an FDA priority review decision for lead drug candidate atacicept.

At a share price of $39.96, Vera’s recent 7 day share price return of 2.54% sits against a 30 day share price return decline of 5.35% and a 90 day share price return decline of 17.27%. The 1 year total shareholder return of 42.36% and very large 3 year total shareholder return suggest longer term holders have seen strong gains as attention builds around the FDA priority review and the addition of experienced board member Christopher Hite.

If you want to see what else is moving around breakthrough therapies, it could be worth scanning 34 healthcare AI stocks.

With Vera still loss making and trading at $39.96 alongside an intrinsic value estimate that implies a sizeable discount, the real question is whether the market is underestimating atacicept’s potential or is already pricing in future growth.

DCF suggests a large gap to intrinsic value

According to the SWS DCF model, Vera Therapeutics has an estimated future cash flow value of $337.43 per share against the last close of $39.96, which points to a large implied discount.

The DCF approach projects future cash flows, then discounts them back using a required rate of return to get a present value per share. For a clinical stage biotech that is currently loss making with $0 in reported revenue and net income of a $299.615 million loss, this type of model relies heavily on assumptions about when revenue may begin and how margins could evolve as products move through trials and potential commercialization.

Vera is flagged as having earnings forecast to grow 59.92% per year and revenue forecast to grow 51.2% per year, with expectations that it may become profitable within the next 3 years. Those inputs help explain why a cash flow based approach can produce a value many times above the current share price, even though the company is still at a development stage and reported losses have grown over the past 5 years.

Result: DCF fair value of $337.43 (UNDERVALUED)

However, there are clear risks here, including Vera’s current US$299.615 million loss and the possibility of clinical or regulatory setbacks that could challenge confidence in atacicept’s path forward.

Another view on Vera’s valuation

While the SWS DCF model points to a $337.43 intrinsic value and a large implied discount, Vera’s $39.96 share price also sits on a P/B of 4.7x, compared with 3.5x for peers and 2.6x for the wider US Biotechs group, which suggests a richer price tag on today’s balance sheet.

For investors weighing a strong DCF upside against a comparatively expensive P/B, the key question is which signal deserves more weight as the story around atacicept develops.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism around atacicept and concern about current losses and valuation signals, it makes sense to move quickly and test the data for yourself, then weigh up the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Once you have formed a view on Vera, do not stop there. Widen your opportunity set with a focused search for other stocks that fit your style.

• Target potential upside by scanning 49 high quality undervalued stocks that combine attractive pricing with solid fundamentals.
• Strengthen income prospects by reviewing 14 dividend fortresses that aim to pair higher yields with resilient business profiles.
• Prioritise resilience by checking 74 resilient stocks with low risk scores that score well on financial stability and risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.